diazepam has been researched along with Kidney Diseases in 21 studies
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.
diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "1 Eight patients with end-stage renal insufficiency on maintenance haemodialysis, and seven patients with newly diagnosed hyperthyroidism, received a single intravenous dose of diazepam, followed by blood sampling over the next 7 days." | 7.66 | Diazepam kinetics in patients with renal insufficiency or hyperthyroidism. ( Abernethy, DR; Divoll, M; Greenblatt, DJ; Kaschell, HJ; Klehr, U; Ochs, HR, 1981) |
| "The plasma protein binding of diazepam and lidocaine was measured in patients with renal disease (those with uremia, nephrotic syndrome, or who had received a transplant) and in age- and sex- matched control subjects." | 3.66 | Diazepam and lidocaine plasma protein binding in renal disease. ( Davis, D; Grossman, SH; Kitchell, BB; Routledge, PA; Shand, DG, 1982) |
| "1 Eight patients with end-stage renal insufficiency on maintenance haemodialysis, and seven patients with newly diagnosed hyperthyroidism, received a single intravenous dose of diazepam, followed by blood sampling over the next 7 days." | 3.66 | Diazepam kinetics in patients with renal insufficiency or hyperthyroidism. ( Abernethy, DR; Divoll, M; Greenblatt, DJ; Kaschell, HJ; Klehr, U; Ochs, HR, 1981) |
| "Anticonvulsant therapy was among the first areas to benefit from clinical pharmacokinetic studies." | 2.35 | Clinical pharmacokinetics of anticonvulsants. ( Dam, M; Hvidberg, EF, 1976) |
| " Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively)." | 1.28 | Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ( Agoston, S; Vandenbrom, RH; Wierda, JM, 1990) |
| "Omeprazole was rapidly cleared and possessed the characteristics of a high clearance drug; insignificant amounts of 14C-omeprazole were excreted by the kidneys, though metabolites were excreted very rapidly." | 1.27 | Pharmacokinetics and metabolism of omeprazole in man. ( Regårdh, CG, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (76.19) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Gulyassy, PF | 1 |
| Depner, TA | 1 |
| Siegers, CP | 1 |
| Klaassen, CD | 1 |
| Kolenda, KD | 1 |
| Grossman, SH | 1 |
| Davis, D | 1 |
| Kitchell, BB | 1 |
| Shand, DG | 1 |
| Routledge, PA | 1 |
| Vree, TB | 1 |
| Hekster, CA | 1 |
| van der Kleijn, E | 1 |
| Ochs, HR | 1 |
| Greenblatt, DJ | 1 |
| Kaschell, HJ | 1 |
| Klehr, U | 1 |
| Divoll, M | 1 |
| Abernethy, DR | 1 |
| Luyckx, A | 1 |
| Van Cauwenberge, H | 1 |
| Dengler, HJ | 1 |
| Eichelbaum, M | 1 |
| Hvidberg, EF | 1 |
| Dam, M | 1 |
| Suslov, VV | 1 |
| Titarenko, OT | 1 |
| Kul'chitskaia, TK | 1 |
| Kovel'skiĭ, VF | 1 |
| Kangas, L | 1 |
| Kanto, J | 1 |
| Forsström, J | 1 |
| Iisalo, E | 1 |
| Viani, A | 1 |
| Rizzo, G | 1 |
| Carrai, M | 1 |
| Pacifici, GM | 1 |
| Lin, TH | 1 |
| Lin, JH | 1 |
| Tuman, KJ | 1 |
| McCarthy, RJ | 1 |
| Spiess, BD | 1 |
| Ivankovich, AD | 1 |
| Vandenbrom, RH | 1 |
| Wierda, JM | 1 |
| Agoston, S | 1 |
| Regårdh, CG | 1 |
| Port, FK | 1 |
| Fiegel, P | 1 |
| Hecking, E | 1 |
| Köhler, H | 1 |
| Distler, A | 1 |
| Wieck, HH | 1 |
| Ulrich, G | 1 |
| Leinzinger, E | 2 |
4 reviews available for diazepam and Kidney Diseases
| Article | Year |
|---|---|
Impaired binding of drugs and endogenous ligands in renal diseases.
Topics: Apazone; Bilirubin; Binding Sites; Carrier Proteins; Diazepam; Digitoxin; Fatty Acids, Nonesterified | 1983 |
[The importance of the biliary excretion of drugs in the human].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bile; Biological Transport; Cardiac Glycosides; Contra | 1983 |
[Drug catabolism and its significance for pharmacotherapy].
Topics: Biotransformation; Cytochrome P-450 Enzyme System; Diazepam; Digitoxin; Digoxin; Drug Interactions; | 1980 |
Clinical pharmacokinetics of anticonvulsants.
Topics: Administration, Oral; Adult; Aged; Aging; Animals; Anticonvulsants; Carbamazepine; Child; Clonazepam | 1976 |
17 other studies available for diazepam and Kidney Diseases
| Article | Year |
|---|---|
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
Diazepam and lidocaine plasma protein binding in renal disease.
Topics: Adult; Aged; Blood Proteins; Diazepam; Fatty Acids, Nonesterified; Female; Humans; Kidney Diseases; | 1982 |
Significance of apparent half-lives of a metabolite with a higher elimination rate than its parent drug.
Topics: Diazepam; Glucuronates; Half-Life; Humans; Kidney Diseases; Metabolic Clearance Rate; Oxazepam; Phar | 1982 |
Diazepam kinetics in patients with renal insufficiency or hyperthyroidism.
Topics: Diazepam; Female; Humans; Hyperthyroidism; Kidney Diseases; Kinetics; Male; Middle Aged; Time Factor | 1981 |
[Therapeutic news of 1975].
Topics: Bismuth; Cardiovascular Diseases; Diazepam; Drug Therapy; Endocrine System Diseases; Gastrointestina | 1976 |
[Polymorphisms and deficient drug metabolism as triggers of toxic reactions (author's transl)].
Topics: Animals; Antipyrine; Cyclacillin; Diazepam; Drug-Related Side Effects and Adverse Reactions; Humans; | 1977 |
[Effect of seduxen on kidney function].
Topics: Adult; Diazepam; Drug Evaluation; Female; Humans; Kidney; Kidney Diseases; Male; Preanesthetic Medic | 1975 |
The protein binding of diazepam and N-demethyldiazepam in patients with poor renal function.
Topics: Adolescent; Adult; Aged; Creatinine; Diazepam; Female; Humans; Kidney Diseases; Male; Middle Aged; O | 1976 |
The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Blood Proteins; Diazepam; Digitoxin; Humans; Kidn | 1992 |
Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Blood-Brain Barrier; Brain; Devaze | 1990 |
Comparison of anesthetic techniques in patients undergoing heart valve replacement.
Topics: Analysis of Variance; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics; Cardiopulmonary | 1990 |
Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.
Topics: Adult; Aged; Alcohols; Anesthesia; Atracurium; Chromatography, High Pressure Liquid; Diazepam; Half- | 1990 |
Pharmacokinetics and metabolism of omeprazole in man.
Topics: Administration, Oral; Aged; Aging; Anti-Ulcer Agents; Benzimidazoles; Diazepam; Dose-Response Relati | 1986 |
Priapism during regular haemodialysis.
Topics: Adult; Chronic Disease; Diazepam; Glomerulonephritis; Heparin; Home Care Services; Humans; Infusions | 1974 |
[Therapy of severe purulent menigitides].
Topics: Ampicillin; Chlormethiazole; Diazepam; Furosemide; Gentamicins; Humans; Injections, Intravenous; Kid | 1973 |
[Prophylaxis and treatment of eclampsia symptom complex].
Topics: Austria; Bilirubin; Diazepam; Female; Fetal Death; Humans; Hydrogen-Ion Concentration; Kidney Diseas | 1970 |
[Prevention and treatment of eclampsic symptom-complex].
Topics: Apgar Score; Bilirubin; Blood Gas Analysis; Body Weight; Diazepam; Eclampsia; Electroencephalography | 1970 |